Calendario›REGN›REGN7508 · ROXI-ATLAS

REGN7508 · ROXI-ATLAS

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Ensayo de REGENERON PHARMACEUTICALS, INC. en Atrial Fibrillation (AF) (del registro, en inglés).

Fase

Fase 2

Estado

Reclutando pacientes

Participantes

1.200

previstos

Centros

84

Fin del objetivo primario

feb 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, simple ciego. Comenzó en oct 2025.

Qué mide

Incidence of any bleeding (del registro, en inglés) (12 semanas)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07175428), actualizada en sep 2026.